SUmmARY The use of monoclonal antibodies which can be raised to antigens of choice offers a selective and specific approach for the detection of tumours both in vivo and at a cellular level in biopsy specimens. We demonstrate that a monoclonal antibody raised to human teratoma will localise in a teratoma, growing as a xenograft in immune-suppressed mice.
One of the major problems facing oncologists, both clinical and laboratory-based, is the detection of metastatic disease, in particular, minimal residual disease (micrometatastes), when they may be more amenable to various therapeutic regimens. While numerous technological advances in physical diagnostic methods have been made, neither they nor the biochemical or immunological assay of tumour markers in the serum or urine are able to detect micrometastases from bronchial, colorectal, or mammary carcinomas. ' An alternative approach may reside in the use of immunological methods to detect tumour cells either in vivo or in biopsy specimens. This latter approach, which involves the use of immunocytochemistry, may be of profound significance for histopathologists in relation to their role in tumour detection in the future. This is well illustrated by Sloane and his associates,2 who recently reported that it was possible to increase the histological detection rate of bone marrow micrometastases from mammary carcinoma when marrow aspirates were stained immunocytochemically for an antigen (EMA).
Another approach to the detection of metastases involves the in vivo use of radiolabelled antibodies. Success has recently been achieved by some workers3-5 although others have expressed doubt about the clinical applicability of this approach. 6 Most of those studies have used radioantibodies to the ubiquitous carcinoembryonic antigen (CEA Monoclonal antibodies to detect human tumours: an ex specifically, showing that no loss of radioactivity had occurred. As a control for non-specific accumulation of proteins in tumours and tissues, normal mouse IgG was iodinated with '3'I to an equivalent specific activity.
Tumours used for this study had been implanted subcutaneously at varying periods of time between 10 and 21 days before the start of the localisation experiment. 1251-monoclonal antibody and 1311-mouse IgG were injected simultaneously intravenously into the tail vein of tumour-bearing and tumour-free animals, each receiving a total of 10-20 ,uCi of radioactive protein. The animals were subsequently killed by exsanguination between 2 and 96 hours after antibody injection. The tumours and organs were removed, and their radioactivity was assessed in a gammacounter programmed for double isotope measurement.
Results are expressed as: (a) localisation index, ie, the ratio of specific (1251) to non-specific (1311) activity in tumours and organs, divided by the same ratio in the blood; and (b) absolute radioactivity, ie, disintegrations per minute per milligram of wet weight (dpm/mg). We consider the localisation index to be an accurate expression of results, because it allows specific and non-specific uptake in tumours and organs to be compared, while simultaneously the relative blood concentrations are taken into account. This parameter also provides a standardised method of comparing values between various experiments.
Autoradiography was used to examine the pattern of accumulated monoclonal antibody within the tumour at a histological level. Tumours and other tissues were fixed in formol saline, conventionally processed, and embedded in paraffin wax, after which 5 mu sections were cut. The tissue sections on slides were dipped in Ilford K5 emulsion at 55°C for 2 seconds and, after drying, were put in light-tight boxes and exposed for four to 35 days. They were subsequently developed (Kodak D19), fixed (AMFIX), and lightly counterstained with haematoxylin and eosin. Various pilot experiments were performed to establish the optimal exposure, subsequent processing, and staining. The slides were examined under both bright and dark field illumination. Calculations of radioactivity loss from the tumour during fixation and processing showed that only 9% to 15% of specific (1251) Whereas the localisation indices in the organs ranged between 1-2 and 1-7 (the liver showed the highest uptake and the intestine the lowest), in the tumour the index is between 2-0 and 5-0 (Table) and in some tumours it reached 8-0. When the absolute amounts of radioactivity are considered, the tumour uptake is between six times higher than liver and 17 times higher than intestine. From a further study of over 100 tumours in 69 animals (including unilateral and bilateral implantations), it has been consistently observed that the smaller the tumour the better the localisation (Fig. 3) .
Autoradiography shows that the radiolabelled monoclonal antibody is seen only in viable parts of the tumour. Areas of necrosis and stromal tissue are generally devoid of grains. The antibody uptake follows two patterns. In the first, there is a high subcapsular concentration of radioactivity at the periphery of the tumour (Fig 4) . In the second pattern, scattered groups of highly concentrated grains are noted within the substance of the tumour, distant from the periphery. In most areas, the grains are seen around the periphery of the tumour cells (Fig. 3) . Positive and negative chemography controls 
Discussion
The recent successful use of radiolabelled antibodies to detect in vivo both primary and metastatic tumours has reawakened interest in this sphere of laboratory-orientated diagnostic activity.3-5 In those studies, affinity-purified antibodies to CEA were employed. As CEA has a wide distribution in both normal and neoplastic tissues,'2 the use of antibodies with a higher degree of specificity would be advantageous. Monoclonal antibodies,7 which can be raised to antigens of choice, offer this possibility. Already, Ballou and his colleagues,13 using monoclonal antibodies against a murine teratoma, have successfully shown that radiolocalisation of tumours by y-scanning is feasible.
Our results indicate that xenografts of human tumours can serve as ideal model systems to test the suitability of various monoclonal antibodies for radioimmunodetection. Using the present human teratoma xenograft model, we have found that the specific monoclonal antibody is taken up considerably more than non-specific IgG and that this specific uptake is considerably higher than in normal organs (Table) . For tumour immunodetection by scanning to be possible, the tumour specific uptake should not only be greater than that of other organs but also be well above that of blood at the time of scanning. This has not been achieved by using conventionally raised antisera, and, therefore, reliance has had to be placed upon computerised blood-pool background subtraction.34 The results achieved to date demonstrate that in this system the levels of specific radioactivity localised in the tumour are such that blood-pool background subtraction and its limitations can be discarded, thereby facilitating camera localisation. Such scanning experiments are now in progress.
In our model system, the weight of the tumour is critical in obtaining optical localisation. Small tumours show the highest degree of specific uptake. This pattern is consistent in all our experiments.
Furthermore, it is seen in any one animal which carries two tumours of different weights. One reason may be related to the appreciably greater amounts of necrosis in larger tumours. This observation, if true for other tumour systems and if it persists in the clinical situation, may be most valuable in assisting with micrometastatic detection.
The collection of radiolabelled monoclonal antibody in the periphery of the tumour and in scattered groups within the tumour may be related to the vascular architecture. However, the importance of our autoradiographic studies lies in the demonstration that the specific radioactivity is located around viable tumour cells.
On the basis of our present results, we now plan to study the immunodiagnostic and therapeutic potential of this and other monoclonal antibodies in the in vivo clinical situation and at an immunocytochemical level in biopsies from sites where metastases from various tumours are known to occur. This latter approach has already been shown to be capable of detecting the presence of isolated small foci of metastases, even in the form of isolated single tumour cells.2
